Eye and/or orbit involvement occurs in Granulomatosis with polyangiitis (GPA) patients frequently. The aim of our study was to describe the clinical manifestations, therapy and outcome of ocular involvement in our GPA patients. A retrospective study was conducted including patients with GPA who followed up in Rheumatology clinics during 1990-2016 at King Khalid University Hospital, Riyadh. Information relating to demographics, ocular manifestations, laboratory findings, therapy and outcome of GPA patients were noted. Ocular involvement was detected in 9 (39.1%) of the 23 GPA cases identified. The mean age of ocular GPA patients was 51.8 (range 27 - 62) years, the mean age at onset of disease was 39.6 (range 11 - 57) years and the mean duration of disease was 9.0 (range 2 - 19) years. Concomitant ear, nose, throat and sino-nasal manifestations occurred with ocular symptoms in 77.8% GPA patients. The most frequent manifestations were, eye pain (66.7%), scleritis/episcleritis (55.6%), eye redness and itching (55.6% each). Antineutrophil cytoplasmic antibodies (ANCA) were positive in 88.9% patients, 55.6% had c-ANCA and 33.3% had p-ANCA. Infections were observed in 22.2% of patients, which included pneumonia in one patient and esophageal candidiasis and bacterial meningitis in another. All patients received oral prednisolone, 44.4% received intravenous cyclophosphamide, 22.2% refractory cases received rituximab doses and the disease outcome was good. Comparison of ocular GPA with non-ocular GPA patients showed that 77.8% of ocular GPA patients had concomitant sino-nasal symptoms compared to 42.9% in non-ocular GPA patients and 22.2% of the ocular GPA patients had renal involvement compared to 64.3% in non-ocular GPA patients (p = 0.049). We found that the frequency of ocular manifestations in our GPA patients was similar to reports elsewhere, and the most frequent symptom was eye pain and scleritis/episcleritis.
References
[1]
Hoffman, G.S., Kerr, G.S., Leavitt, R.Y., et al. (1992) Wegener Granulomatosis: An Analysis of 158 Patients. Annals of Internal Medicine, 116, 488-498. https://doi.org/10.7326/0003-4819-116-6-488
[2]
Jennette, J.C. (2011) Nomenclature and Classification of Vasculitis: Lessons Learned from Granulomatosis with Polyangiitis (Wegener’s Granulomatosis). Clinical and Experimental Immunology, 164, 7-10. https://doi.org/10.1111/j.1365-2249.2011.04357.x
[3]
Ursea, R., De Castro, D., Bowen, T.J. and Chan, C.C. (2015) The Role of Conjunctival Biopsy in the Diagnosis of Granulomatosis with Polyangiitis. The Journal of Ophthalmic Inflammation and Infection, 5, Article No. 1. https://doi.org/10.1186/s12348-014-0033-9
[4]
Rothschild, P.R., Pagnoux, C., Seror, R., et al. (2013) Ophthalmologic Manifestations of Systemic Necrotizing Vasculitides at Diagnosis: A Retrospective Study of 1286 Patients and Review of the Literature. Seminars in Arthritis and Rheumatism, 42, 507-514. https://doi.org/10.1016/j.semarthrit.2012.08.003
[5]
Kubaisi, B., Samra, A.K. and Foster, C.S. (2016) Granulomatosis with Polyangiitis (Wegener’s Disease): An Updated Review of Ocular Disease Manifestations. Intractable & Rare Diseases Research, 5, 61-69. https://doi.org/10.5582/irdr.2016.01014
Gheita, T.A. and Abd El Latif, E.M. (2019) Relationship of Ocular Presentation in Granulomatosis with Polyangiitis to Autoantibodies and Disease Activity. Zeitschrift für Rheumatologie, 78, 281-286. https://doi.org/10.1007/s00393-018-0495-5
[8]
Generali, E., Cantarini, L. and Selmi, C. (2015) Ocular Involvement in Systemic Autoimmune Diseases. Clinical Reviews in Allergy & Immunology, 49, 263-270. https://doi.org/10.1007/s12016-015-8518-3
[9]
Rosenbaum, J.T. (2017) The Eye and Rheumatic Diseases. In: Firestein, G.S., Budd, R.C., Gabriel, S.E., McInnes, I.B. and O’Dell, J.R., Eds., Kelley and Firestein’s Textbook of Rheumatology, Elsevier, Philadelphia, 645-653, Chapter 44.
[10]
Jiang, B., Zhao, Y.Y. and Wei, S.H. (2013) Granulomatosis with Polyangiitis: The Relationship between Ocular and Nasal Disease. Ocular Immunology and Inflammation, 21, 115-118. https://doi.org/10.3109/09273948.2012.747618
[11]
Holle, J.U., Voigt, C., Both, M., et al. (2013) Orbital Masses in Granulomatosis with Polyangiitis Are Associated with a Refractory Course and a High Burden of Local Damage. Rheumatology (Oxford), 52, 875-882. https://doi.org/10.1093/rheumatology/kes382
[12]
Tan, L.T., Davagnanam, I., Isa, H., et al. (2014) Clinical and Imaging Features Predictive of Orbital Granulomatosis with Polyangiitis and the Risk of Systemic Involvement. Ophthalmology, 121, 1304-1309. https://doi.org/10.1016/j.ophtha.2013.12.003
[13]
Boukes, R.J. and de Vries-Knoppert, W.A. (1985) Lacrimal Gland Enlargement as One of the Ocular Manifestations of Wegener’s Granulomatosis. Documenta Ophthalmologica, 59, 21-26. https://doi.org/10.1007/BF00162005
[14]
Kiseleva, T.N., Grusha, I.O., Polunina, A.A., et al. (2009) Involvement of Lacrimal Organs in Wegener’s Granulomatosis. Vestnik oftalmologii, 125, 33-36.
[15]
Howe, L., D’Cruz, D., Chopdar, A., et al. (1995) Anterior Ischaemic Optic Neuropathy in Wegener’s Granulomatosis. European Journal of Ophthalmology, 5, 277-279. https://doi.org/10.1177/112067219500500415
[16]
Jennette, J.C., Falk, R.J., Bacon, P.A., et al. (2013) 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & Rheumatology, 65, 1-11. https://doi.org/10.1002/art.37715
[17]
de Souza, F.H., Radu Halpern, A.S., Valente Barbas, C.S., et al. (2010) Wegener’s Granulomatosis: Experience from a Brazilian Tertiary Center. Clinical Rheumatology, 29, 855-860. https://doi.org/10.1007/s10067-010-1408-4
[18]
Reinhold-Keller, E., Beuge, N., Latza, U., et al. (2000) An Interdisciplinary Approach to the Care of Patients with Wegener’s Granulomatosis: Long-Term Outcome in 155 Patients. Arthritis & Rheumatology, 43, 1021-1032. https://doi.org/10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J
[19]
Matteson, E.L., Gold, K.N. and Bloch, D.A. (1996) Long-Term Survival of Patients with Wegener’s Granulomatosis from the American College of Rheumatology Wegener’s Granulomatosis Classification Criteria Cohort. The American Journal of Medicine, 101, 129-134. https://doi.org/10.1016/S0002-9343(96)80066-0
[20]
Pakrou, N., Selva, D. and Leibovitch, I. (2006) Wegener’s Granulomatosis: Ophthalmic Manifestations and Management. Seminars in Arthritis and Rheumatism, 35, 284-292. https://doi.org/10.1016/j.semarthrit.2005.12.003
[21]
Stone, J.H. and Wegener’s Granulomatosis Etanercept Trial Research Group (2003) Limited versus Severe Wegener’s Granulomatosis: Baseline Data on Patients in the Wegener’s Granulomatosis Etanercept Trial. Arthritis & Rheumatology, 48, 2299-2309. https://doi.org/10.1002/art.11075
[22]
Aldasoro-Cáceres, V., Aldasoro-Cáceres, I., Pérez-Moreiras, J.V., et al. (2014) C-ANCA Positive Necrotizing Scleritis and Multiple Sclerosis Compatible with Ocular Wegener: Treatment with Rituximab. Archivos de la Sociedad Española de Oftalmología, 89, 31-34. https://doi.org/10.1016/j.oftal.2012.06.020
[23]
Solans-Laqué, R., Fraile, G., Rodriguez-Carballeira, M., et al. (2017) Clinical Characteristics and Outcome of Spanish Patients with ANCA Associated Vasculitides: Impact of the Vasculitis Type, ANCA Specificity, and Treatment on Mortality and Morbidity. Medicine (Baltimore), 96, e6083. https://doi.org/10.1097/MD.0000000000006083
[24]
Torres, R.M., Herreras, J.M., Becerra, E., et al. (2004) Ocular Presentation in Wegener Granulomatosis. Archivos de la Sociedad Española de Oftalmología, 79, 135-138. https://doi.org/10.4321/S0365-66912004000300008
[25]
Hinojosa-Azaola, A., García-Castro, A., Juárez-Flores, A., et al. (2019) Clinical Significance of Ocular Manifestations in Granulomatosis with Polyangiitis: Association with Sinonasal Involvement and Damage. Rheumatology International, 39, 489-495. https://doi.org/10.1007/s00296-019-04242-7
[26]
Akpek, E.K., Uy, H.S., Christen, W., et al. (1999) Severity of Episcleritis and Systemic Disease Association. Ophthalmology, 106, 729-731. https://doi.org/10.1016/S0161-6420(99)90157-4
[27]
Sainz de la Maza, M., Foster, C.S. and Jabbur, N.S. (1995) Scleritis Associated with Systemic Vasculitic Diseases. Ophthalmology, 102, 687-692. https://doi.org/10.1016/S0161-6420(95)30970-0
[28]
Chung, S. and Monach, P.A. (2017) Anti-Neutrophil Cutoplasmic Antibody-Associated Vasculitis. In: Firestein, G.S., Budd, R.C., Gabriel, S.E., McInnes, I.B. and O’Dell, J.R., Eds., Kelley and Firestein’s Textbook of Rheumatology, Elsevier, Philadelphia, 1541-1558, Chapter 89. https://doi.org/10.1016/B978-0-323-31696-5.00089-9
[29]
Spalton, D.J., Graham, E.M., Page, N.G., et al. (1981) Ocular Changes in Limited Forms of Wegener’s Granulomatosis. British Journal of Ophthalmology, 65, 553-563. https://doi.org/10.1136/bjo.65.8.553
[30]
Fauci, A.S., Haynes, B.F., Katz, P., et al. (1983) Wegener’s Granulomatosis: Prospective Clinical and Therapeutic Experience with 85 Patients for 21 Years. Annals of Internal Medicine, 98, 76-85. https://doi.org/10.7326/0003-4819-98-1-76
[31]
Woo, T.L., Francis, I.C., Wilcsek, G.A., et al. (2001) Australasian Orbital and Adnexal Wagener’s Study Group. Australasian Orbital and Adnexal Wegener’s Granulomatosis. Ophthalmology, 108, 1535-1543. https://doi.org/10.1016/S0161-6420(01)00655-8
[32]
Tan, L.T., Davagnanam, I., Isa, H., et al. (2015) Clinical and Imaging Features of Lacrimal Gland Involvement in Granulomatosis with Polyangiitis. Ophthalmology, 122, 2125-2129. https://doi.org/10.1016/j.ophtha.2015.06.026
[33]
Ahmed, M., Niffenegger, J.H., Jakobiec, F.A., et al. (2008) Diagnosis of Limited Ophthalmic Wegener’s Granulomatosis: Distinctive Pathologic Features with ANCA Test Confirmation. International Ophthalmology, 28, 35-46. https://doi.org/10.1007/s10792-007-9109-y
[34]
Kalina, P.H., Lie, J.T., Campbell, R.J., et al. (1992) Diagnostic Value and Limitations of Orbital Biopsy in Wegener’s Granulomatosis. Ophthalmology, 99, 120-124. https://doi.org/10.1016/S0161-6420(92)32028-7
[35]
Haubitz, M., Schellong, S., Göbel, U., et al. (1998) Intravenous Pulse Administration of Cyclophosphamide versus Daily Oral Treatment in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and Renal Involvement: A Prospective, Randomized Study. Arthritis & Rheumatology, 41, 1835-1844. https://doi.org/10.1002/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q
[36]
Joshi, L., Tanna, A., McAdoo, S.P., et al. (2015) Long-Term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis: Impact on Localized and Nonlocalized Disease. Ophthalmology, 122, 1262-1268. https://doi.org/10.1016/j.ophtha.2015.01.016
[37]
Bitik, B., Kılıç, L., Küçükşahin, O., et al. (2015) Retro-Orbital Granuloma Associated with Granulomatosis with Polyangiitis: A Series of Nine Cases. Rheumatology International, 35, 1083-1092. https://doi.org/10.1007/s00296-014-3179-8
[38]
Joshi, L., Lightman, S.L., Salama, A.D., et al. (2011) Rituximab in Refractory Ophthalmic Wegener’s Granulomatosis: PR3 Titers May Predict Relapse, But Repeat Treatment Can Be Effective. Ophthalmology, 118, 2498-2503. https://doi.org/10.1016/j.ophtha.2011.06.009
[39]
Baslund, B., Wiencke, A.K., Rasmussen, N., et al. (2012) Treatment of Orbital Inflammation with Rituximab in Wegener’s Granulomatosis. Clinical and Experimental Rheumatology, 30, S7-S10.
[40]
El-Shabrawi, Y. and Hermann, J. (2005) Anti-TNF Alpha Therapy in Chronic Necrotizing Scleritis Resistant to Standard Immunomodulatory Therapy in a Patient with Wegener’s Granulomatosis. Eye, 19, 1017-1018. https://doi.org/10.1038/sj.eye.6701712
[41]
Kontkanen, M., Paimela, L. and Kaarniranta, K. (2010) Regression of Necrotizing Scleritis in Wegener’s Granulomatosis after Infliximab Treatment. Acta Ophthalmologica, 88, e96-e97. https://doi.org/10.1111/j.1755-3768.2009.01546.x
[42]
Wieringa, W.G., Wieringa, J.E., ten Dam-van Loon, N.H., et al. (2013) Visual Outcome, Treatment Results, and Prognostic Factors in Patients with Scleritis. Ophthalmology, 120, 379-386. https://doi.org/10.1016/j.ophtha.2012.08.005
